H. Herfarth
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
H. Herfarth has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
G. Rogler
Department of Internal Medicine I, Regensburg
1 shared publicationH. C. Rath
Department of Internal Medicine I, Regensburg
1 shared publicationJ. Schölmerich
Department of Internal Medicine I, Regensburg
1 shared publicationK. Brand
Department of Clinical Chemistry and Pathobiochemistry, Klinikum re. d. Isar, Munich, Germany
1 shared publicationW. Falk
Department of Internal Medicine I, Regensburg
1 shared publication
Latest Publications
- Open Access
- 1 April 2000
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 120 (1) , 59-65
Nuclear factor-κB activity and intestinal inflammation in dextran sulphate sodium (DSS)-induced colitis in mice is suppressed by gliotoxin
In acute DSS‐induced colitis nuclear factor (NF)‐κB‐dependent inflammatory cytokines including IL‐1 and tumour necrosis factor‐alpha (TNF‐α) are up‐regulated. Here we examined the effects of gliotoxin, a fungal metabolite known to inhibit NF‐κB activity, on cytokine production by a mouse cell system in vitro and on intestinal inflammation and NF‐κB activation in vivo. In vitro gliotoxin decreased TNF‐α gene expression and protein production by RAW‐264.7 mouse macrophage‐like cells stimulated with lipopolysaccharide. In vivo, gliotoxin treatment of mice was begun on day 3 of 5% DSS application dissolved in the drinking water and continued until day 8. Gliotoxin treatment dose‐dependently down‐regulated colonic inflammation as assessed histologically and in parallel there was a suppression of colonic TNF‐α and IL‐1α mRNA expression on day 8 as analysed by semiquantitative reverse transcriptase‐polymerase chain reaction (P < 0·01). Furthermore, colonic NF‐κB DNA‐binding activity was increased in DSS‐induced colitis and was suppressed by gliotoxin. These results demonstrate the essential role of NF‐κB in DSS‐induced colitis and indicate a molecular approach to the treatment of intestinal inflammatory disorders.
- 1 April 2000
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 120 (1) , 59-65
Open AccessNuclear factor-κB activity and intestinal inflammation in dextran sulphate sodium (DSS)-induced colitis in mice is suppressed by gliotoxin
In acute DSS‐induced colitis nuclear factor (NF)‐κB‐dependent inflammatory cytokines including IL‐1 and tumour necrosis factor‐alpha (TNF‐α) are up‐regulated. Here we examined the effects of gliotoxin, a fungal metabolite known to inhibit NF‐κB activity, on cytokine production by a mouse cell system in vitro and on intestinal inflammation and NF‐κB activation in vivo. In vitro gliotoxin decreased TNF‐α gene expression and protein production by RAW‐264.7 mouse macrophage‐like cells stimulated with lipopolysaccharide. In vivo, gliotoxin treatment of mice was begun on day 3 of 5% DSS application dissolved in the drinking water and continued until day 8. Gliotoxin treatment dose‐dependently down‐regulated colonic inflammation as assessed histologically and in parallel there was a suppression of colonic TNF‐α and IL‐1α mRNA expression on day 8 as analysed by semiquantitative reverse transcriptase‐polymerase chain reaction (P < 0·01). Furthermore, colonic NF‐κB DNA‐binding activity was increased in DSS‐induced colitis and was suppressed by gliotoxin. These results demonstrate the essential role of NF‐κB in DSS‐induced colitis and indicate a molecular approach to the treatment of intestinal inflammatory disorders.